You are here

cancer

Vedanta Biosciences initiates first-in-patient study of VE800 in combination with Bristol-Myers Squibb’s Opdivo

Vedanta Biosciences initiates first-in-patient study of VE800 in combination with Bristol-Myers Squibb’s Opdivo

Pharmaceutical Business Review

Vedanta Biosciences

Bristol-Myers Squibb

clinical trials

Flag link:

AbbVie and Scripps Research Enter Research Partnership in Cancer, Immunology, Neurology and Fibrosis

AbbVie and Scripps Research Enter Research Partnership in Cancer, Immunology, Neurology and Fibrosis

BioSpace

Scripps Research Institute

Flag link:

ASH19: AZ’s Calquence throws gauntlet down to Imbruvica

ASH19: AZ’s Calquence throws gauntlet down to Imbruvica

Pharmaforum

Flag link:

Why The Obsession With A Universal Cure For Cancer May Be Harming Research And Patients

Why The Obsession With A Universal Cure For Cancer May Be Harming Research And Patients

Forbes

universal cancer vaccine

Flag link:

Lilly puts its cancer future in Loxo's hands

Lilly puts its cancer future in Loxo's hands

Biopharma Dive

Flag link:

How a New Method is Improving Whole Genome Sequencing of FFPE Tumor Tissues

How a New Method is Improving Whole Genome Sequencing of FFPE Tumor Tissues

Xtalks

genome sequencing

Flag link:

Roche under fire again: Mylan launches Herceptin copycat in latest blow to blockbuster trio

Roche under fire again: Mylan launches Herceptin copycat in latest blow to blockbuster trio

Fierce Pharma

Flag link:

Another cancer vaccine play out of Geneva shoots for 'hard endpoint' in PhII head and neck cancer test

Another cancer vaccine play out of Geneva shoots for 'hard endpoint' in PhII head and neck cancer test

Endpoints

cancer vaccines

head and neck cancer

Flag link:

Teva forms academic R&D pacts to further biopharma strategy

Teva forms academic R&D pacts to further biopharma strategy

Fierce Biotech

Teva Pharmaceutical

Flag link:

2 Small-Cap Biotechs That Soared Last Week

2 Small-Cap Biotechs That Soared Last Week

Motley Fool

Magenta Therapeutics

Molecular Templates

Flag link:

AstraZeneca CEO: Closing In On A Cancer Cure

AstraZeneca CEO: Closing In On A Cancer Cure

Yahoo/Benzinga

Flag link:

With Cell-By-Cell Take on Drug Discovery, Immunitas Debuts With $39M

With Cell-By-Cell Take on Drug Discovery, Immunitas Debuts With $39M

Xconomy

Immunitas Therapeutics

single-cell genomics

Flag link:

AstraZeneca, Merck win red carpet treatment at the FDA as a 3-time loser seeks speedy OK for rare tumors

AstraZeneca, Merck win red carpet treatment at the FDA as a 3-time loser seeks speedy OK for rare tumors

Endpoints

Flag link:

Bolt Bio preps clinical trials of immune-stimulating cancer drug in stubborn solid tumors

Bolt Bio preps clinical trials of immune-stimulating cancer drug in stubborn solid tumors

Fierce Biotech

Bolt Biotherapeutics

immuno-oncology

clinical trials

Flag link:

First use of CRISPR against cancer in patients clears early safety hurdles

First use of CRISPR against cancer in patients clears early safety hurdles

Stat

Flag link:

Radius plans to cut loose oncology assets

Radius plans to cut loose oncology assets

Fierce Biotech

endocrine disorders

Flag link:

A2 Biotherapeutics emerges from stealth mode to develop tumour cell therapeutics

A2 Biotherapeutics emerges from stealth mode to develop tumour cell therapeutics

Pharmaceutical Business Review

A2 Biotherapeutics

Flag link:

It took a 3-year struggle, but Novartis finally gets a green light on their copycat to Amgen's big blockbuster

It took a 3-year struggle, but Novartis finally gets a green light on their copycat to Amgen's big blockbuster

Endpoints

Flag link:

CMS proposes lifting restrictions on NGS cancer testing

CMS proposes lifting restrictions on NGS cancer testing

Biopharma Dive

next generation sequencing

Flag link:

Sanofi axes cancer combo, early next-gen diabetes drug

Sanofi axes cancer combo, early next-gen diabetes drug

Fierce Biotech

Flag link:

Pages